ES2081531T3 - Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales. - Google Patents

Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.

Info

Publication number
ES2081531T3
ES2081531T3 ES92113603T ES92113603T ES2081531T3 ES 2081531 T3 ES2081531 T3 ES 2081531T3 ES 92113603 T ES92113603 T ES 92113603T ES 92113603 T ES92113603 T ES 92113603T ES 2081531 T3 ES2081531 T3 ES 2081531T3
Authority
ES
Spain
Prior art keywords
vintages
pharmaceutical compositions
rifaximine
treatment
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92113603T
Other languages
English (en)
Inventor
Egidio Marchi
Leone Gabriele Rotini
Subhash Desai
Massimo Grilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Application granted granted Critical
Publication of ES2081531T3 publication Critical patent/ES2081531T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS VAGINALES PARA ADMINISTARLAS POR VIA TOPICA, EN PARTICULAR A MODO DE ESPUMAS VAGINALES Y POMADAS QUE CONTIENEN UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE RIFAXIMIN (DENOMININACION COMUN INTERNACIONAL) Y SON UTILES EN EL TRATAMIENTO DE INFECCIONES VAGINALES, EN PARTICULAR DE LA VAGINOSIS BACTERIANA.
ES92113603T 1991-12-17 1992-08-10 Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales. Expired - Lifetime ES2081531T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO910476A IT1253711B (it) 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali

Publications (1)

Publication Number Publication Date
ES2081531T3 true ES2081531T3 (es) 1996-03-16

Family

ID=11337881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92113603T Expired - Lifetime ES2081531T3 (es) 1991-12-17 1992-08-10 Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.

Country Status (13)

Country Link
US (2) US5314904A (es)
EP (1) EP0547294B1 (es)
JP (1) JP2834951B2 (es)
KR (1) KR0149519B1 (es)
AT (1) ATE130510T1 (es)
CA (1) CA2073601C (es)
DE (1) DE69206245T2 (es)
DK (1) DK0547294T3 (es)
ES (1) ES2081531T3 (es)
GR (1) GR3018205T3 (es)
IT (1) IT1253711B (es)
MX (1) MX9204132A (es)
TW (1) TW217385B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6462030B1 (en) * 1999-07-19 2002-10-08 New York Blood Center, Inc. Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methycellulose phthalate
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6706276B2 (en) 2000-03-07 2004-03-16 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6537538B2 (en) 2000-12-18 2003-03-25 Rush-Presbyterian-St. Luke's Medical Center Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
KR100392363B1 (ko) * 2000-12-26 2003-07-22 한국전자통신연구원 형광체 및 그 제조방법
US7033604B2 (en) * 2001-07-06 2006-04-25 Sucampo Ag Composition for topical administration
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
NZ540166A (en) 2002-10-25 2007-06-29 Foamix Ltd Cosmetic and pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
ES2385477T3 (es) 2002-11-05 2012-07-25 Fadim S.R.L. Liberación continua y controlada de rifaximina
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
ES2752773T3 (es) * 2003-06-13 2020-04-06 Idh Holding Aps Tratamiento de los síntomas asociados a la vaginosis bacteriana
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
AU2004274000B2 (en) 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
PT1708686E (pt) * 2003-12-31 2011-04-20 Cima Labs Inc Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
JP5244318B2 (ja) * 2003-12-31 2013-07-24 シーマ・ラブス、インコーポレイテッド 発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2006298442A1 (en) * 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
JP2008540534A (ja) * 2005-05-09 2008-11-20 ドラッグテック コーポレイション 放出調節薬学組成物
CN101365425A (zh) * 2006-01-05 2009-02-11 药物技术公司 用于生物粘附到外阴阴道表面的递药系统
US20070224226A1 (en) * 2006-01-05 2007-09-27 Drugtech Corporation Composition and method of use thereof
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
EP2837378A1 (en) * 2007-07-06 2015-02-18 Lupin Limited Pharmaceutical compositions of rifaximin
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
RU2011116400A (ru) 2008-09-26 2012-11-10 Аска Фармасьютикал Ко., Лтд. (Jp) Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
KR101972354B1 (ko) * 2009-10-27 2019-04-25 루핀 리미티드 리팍시민의 고형 분산물
EP2503989A2 (en) * 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US20130202654A1 (en) * 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
US8445226B2 (en) 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
CN105142636A (zh) 2013-03-15 2015-12-09 意大利阿尔法韦士曼制药公司 用于治疗阴道感染的利福昔明
PT3143027T (pt) 2014-05-12 2019-09-20 Alfasigma Spa Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
AU2015311674B2 (en) 2014-09-05 2018-03-08 Evofem Biosciences, Inc. Secnidazole for use in the treatment of bacterial vaginosis
EP3261683B1 (en) 2015-02-26 2019-01-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Topical composition for the treatment of mucosal lesions
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
US20190008784A1 (en) * 2017-07-07 2019-01-10 Symbiomix Therapeutics, Llc Novel secnidazole soft gelatin capsule formulations and uses thereof
WO2019073321A1 (en) * 2017-10-10 2019-04-18 Zenvision Pharma Llp EFFERVESCENT COMPOSITIONS COMPRISING RIFAXIMINE
US20230398102A1 (en) * 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA816635B (en) * 1980-09-25 1982-09-29 Ciba Geigy Novel 2-aminoimidazoles
EP0049683A3 (de) * 1980-09-25 1982-09-01 Ciba-Geigy Ag Imidazo-Rifamycine, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Präparate sowie ihre Verwendung
IT1190445B (it) * 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
ATE109978T1 (de) * 1989-03-31 1994-09-15 Lepetit Spa Verwendung von purpuromycin zur behandlung von vaginalinfektionen.
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
GB9001019D0 (en) * 1990-01-17 1990-03-14 Euro Celtique Sa Pharmaceutical aerosol

Also Published As

Publication number Publication date
ITBO910476A0 (it) 1991-12-17
US6140355A (en) 2000-10-31
DK0547294T3 (da) 1995-12-18
GR3018205T3 (en) 1996-02-29
TW217385B (es) 1993-12-11
ATE130510T1 (de) 1995-12-15
DE69206245D1 (de) 1996-01-04
KR930012015A (ko) 1993-07-20
DE69206245T2 (de) 1996-05-02
CA2073601A1 (en) 1993-06-18
IT1253711B (it) 1995-08-23
EP0547294B1 (en) 1995-11-22
EP0547294A1 (en) 1993-06-23
JP2834951B2 (ja) 1998-12-14
CA2073601C (en) 1996-07-09
MX9204132A (es) 1993-08-01
KR0149519B1 (ko) 1998-10-15
JPH05255085A (ja) 1993-10-05
ITBO910476A1 (it) 1993-06-17
US5314904A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ES2159591T3 (es) Composicion de liberacion controlada.
TWI232219B (en) Compounds containing cyclohexane group, process for preparing them and pharmaceutical composition containing them
EP0668720A4 (en) M-EDTA PHARMACEUTICAL PREPARATIONS AND THEIR USE.
ES2117015T3 (es) Composiciones que contienen sumatriptan.
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
MX9200361A (es) Nuevo uso del antagonista de adenosina.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
ES2129078T3 (es) Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
PA8515601A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
ES2133152T3 (es) Composicion de tiotepa liofilizada estable.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES2039289T3 (es) Composiciones farmaceuticas para uso topico conteniendo miocamicina.
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
IT1263222B (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
DE602004022578D1 (de) Antitumorale terpen-verbindungen
CO5580790A2 (es) Composicion farmaceutica de fondaparinux sodio para el tratamiento de acs

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 547294

Country of ref document: ES